Navigation Links
Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion
Date:9/28/2010

eagher & Flom LLP are acting as Endo's legal counsel.  JPMorgan Chase Bank N.A. and RBC Capital Markets are providing financing commitments.

J.P. Morgan Securities LLC is acting as exclusive financial advisor to Qualitest Pharmaceuticals and Kirkland & Ellis LLP are acting as Qualitest Pharmaceuticals' legal counsel.  

Conference Call and Webcast InformationEndo's management team will host a conference call and audio webcast on Tuesday, September 28 at 8:30 a.m. EDT to discuss this transaction. Interested parties may call 866-356-3095 (domestic) or 617-597-5391 (international) and enter code 18751869. Please dial in 15 minutes prior to the scheduled start time. A replay of the call will be available until 11:59 p.m. EDT on October 12 by dialing 888-286-8010 (domestic) or 617-801-6888 (international), passcode 52263898.

A simultaneous audio Webcast of the call may be accessed by visiting www.endo.com. A replay of the Webcast will be available until 11:59 p.m. EDT on October 12. The replay can be accessed by clicking on "Events" in the Investor Relations section of the Website. Please connect to the Website at least 15 minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.Reconciliation of Projected GAAP Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share GuidanceYear EndingDecember 31, 2010Projected GAAP diluted income per common share$1.88To$1.96 Upfront and milestone-related payments to partners

$0.38 $0.33 Amortization of commercial intangible assets

$0.59 $0.59 Costs incurred in connection with continued efforts to enhance the cost structure of the Company

$0.08$0.08Indevus related costs and change in fair value of contingent consideration

$0.01$0.01Impairment of indefinite-lived intangibles

$0.11$0.11Costs related to the acquisition of HealthTronics, Inc.

$0.30$0
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... -- Following the reintroduction of the Comprehensive Addiction ... a report today urging policymakers to take steps ... through more effective use of medication-assisted treatment (MAT).  ... Expanding Access to Medication-Assisted Treatment to Address the ... and economic advantages of medication-assisted treatment along with ...
(Date:3/4/2015)... , March 4, 2015  Heska Corporation (Nasdaq: ... Invites You to Join Its Fourth Quarter and Year ... 5, 2015 @ 9:00 a.m. (MST) / 11:00 a.m. ... End 2014 Earnings Call link on the front page ... on to the web at the address above.  Alternatively, ...
(Date:3/4/2015)... March 4, 2015   InspireMD, Inc.  ("InspireMD" or ... protection systems ("EPS"), today announced that it has entered ... 34 million shares of common stock and warrants to ... stock in a public offering.  The common stock will ... per share, and each purchaser will receive a warrant ...
Breaking Medicine Technology:Improved Medication-Assisted Treatment Policy Could Aid Epidemic of 20 Million Americans with Untreated Addiction 2Webcast Alert: Heska Announces Fourth Quarter and Year End 2014 Earnings Conference Call Webcast 2InspireMD Announces Public Offering for Approximately $13.5 Million 2InspireMD Announces Public Offering for Approximately $13.5 Million 3InspireMD Announces Public Offering for Approximately $13.5 Million 4
... Jan. 3, 2012  theVisualMD, www.thevisualmd.com , the world,s leading ... initiative, The 9 Visual Rules of Wellness. Quest Diagnostics (NYSE: ... testing, information and services, is the official sponsor of the ... 9 Visual Rules of Wellness aim to bring readers a ...
...  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) and Eisai ... the Complete Response Letter (CRL) issued by the US Food ... Drug Application (NDA). Lorcaserin is intended for weight management, including ... are obese (Body Mass Index, or BMI, >30) or patients ...
Cached Medicine Technology:theVisualMD Launches a Revolutionary New Visual Path to Wellness 2theVisualMD Launches a Revolutionary New Visual Path to Wellness 3theVisualMD Launches a Revolutionary New Visual Path to Wellness 4Arena Submits Response to FDA Complete Response Letter for Lorcaserin 2Arena Submits Response to FDA Complete Response Letter for Lorcaserin 3Arena Submits Response to FDA Complete Response Letter for Lorcaserin 4Arena Submits Response to FDA Complete Response Letter for Lorcaserin 5Arena Submits Response to FDA Complete Response Letter for Lorcaserin 6
(Date:3/4/2015)... 04, 2015 With the growing influence of ... of our teens and young adults, combined with the increasingly ... confusing to try to keep up with what kids are ... trend is replaced on a daily basis. , The same ... the slang that is used to discreetly talk about them, ...
(Date:3/4/2015)... 04, 2015 More than a year ... potentially associated with low testosterone treatments ( http://www.testosteronelawsuithub.com/ ), ... it will now require manufacturers to warn patients that ... heart attacks and strokes. In a Drug Safety ... stated that it was requiring testosterone manufacturers to update ...
(Date:3/4/2015)... Vancouver chiropractic clinic, Backs in Action ... the prestigious Vancouver Courier “Stars of Vancouver” 2015 ... company secured third place in the “Best Chiropractor” ... Massage Therapist” category. , As one of ... Vancouver Courier is a semiweekly local newspaper published ...
(Date:3/4/2015)... 2015 The print component of “Organic ... Francisco Chronicle with a circulation of approximately 173,000 copies ... component is distributed nationally through a vast social media ... and partner outlets. To explore the digital version of ... is composed of heat-dried microbes that have digested the ...
(Date:3/4/2015)... Atlanta, Georgia (PRWEB) March 04, 2015 ... Georgia, part of the School of Public Health at ... , The funds were awarded by Georgia’s Division of ... contract to support the DFCS Call Center. , ... child maltreatment by providing information and referral services that ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom Offers Guide to Parents for Keeping Youth Sober 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4Health News:Backs in Action Receives Two Awards in The Vancouver Courier Readers’ Choice Awards 2015 2Health News:State Funds Child Abuse Helpline Housed At Georgia State 2
... adults of industrialized countries is approximately 10% and is ... is scarce. , A research article published ... Gastroenterology addresses this problem. The team lead by Dr. ... Canada, has reviewed the rate of gallstone disease and ...
... means of microsatellite markers has become an effective way ... candidate tumor suppressor genes. In a previous study, it ... frequencies, which indicated that the region might harbor the ... contained so many genes that it was inconvenient to ...
... Intraductal papillary neoplasm of the bile duct (IPN-B) is ... is a new definition of a tumor with papillary ... authors reported a case of IPN-B with interesting histopathological ... the diagnosis of bile duct dilatation due to the ...
... ARNA ) today announced it will report first ... on Wednesday, May,7, 2008. That same afternoon, Jack Lief, ... Arena,s Vice President, Finance,and Chief Financial Officer, will host ... Pacific Time) to discuss the first quarter 2008,financial results ...
... 30 The following is an,editorial from The Wall ... Committee:, [J]ohn McCain delivered another speech yesterday on ... could lead to some of the most,constructive changes to ... for his candidacy if Mr. McCain is making space ...
... FRAZER, Pa., April 30 Cephalon, Inc. (Nasdaq:,CEPH) ... Executive Vice,President and General Counsel. In this position, ... company, including those relating to commercial,and financial transactions, ... directly to Chairman and CEO, Frank,Baldino Jr., Ph.D., ...
Cached Medicine News:Health News:A patient who was diagnosed as IPN-B without hepatolithiasis? 2Health News:Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008 2Health News:Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008 3Health News:RNC: McCain's Progress 2Health News:Cephalon Appoints Gerald J. Pappert as General Counsel 2Health News:Cephalon Appoints Gerald J. Pappert as General Counsel 3
AnkleWALKER™ Shorter uprights and circumferential plastic shell inhibit foot and ankle motion. Designed to provide comfortable stability for acute ankle sprains, soft tissue injuries, stress an...
... The FoamWalker is a cost-effective walking ... support. It has a lightweight, durable, semi-rigid ... protection. The shell's rocker sole helps reduce ... two aircells for compression and support at ...
... VACOPED is a revolutionary cast replacement ... the lower leg and foot. , ... patient's anatomy and in conjunction with a ... the general time of fracture or rupture ...
... of controlled compression and cold, the Calf ... anatomically designed cuff provides complete calf coverage ... as a single cuff, or with a ... disk). The Cooler is available separately and ...
Medicine Products: